EFEK PEMBERIAN METFORMIN DAN TELMISARTAN TERHADAP RESISTENSI INSULIN PADA PASIEN SINDROM METABOLIK DENGAN TERAPI INSULIN

Background: Recommendations for therapy of insulin resistance are metformin and thiazolidindion. Side effects of thiazolidindion due to peripheral edema occurs to 2- 5% and increased 5-15% when combined with insulin therapy. Telmisartan, an angiotensin receptor blocker, has anti-hypertensive effects...

Full description

Bibliographic Details
Main Authors: , Siswi Oktariani, , Dr. R. Bowo Pramono, SpPD-KEMD
Format: Thesis
Published: [Yogyakarta] : Universitas Gadjah Mada 2013
Subjects:
ETD
_version_ 1826047008677298176
author , Siswi Oktariani
, Dr. R. Bowo Pramono, SpPD-KEMD
author_facet , Siswi Oktariani
, Dr. R. Bowo Pramono, SpPD-KEMD
author_sort , Siswi Oktariani
collection UGM
description Background: Recommendations for therapy of insulin resistance are metformin and thiazolidindion. Side effects of thiazolidindion due to peripheral edema occurs to 2- 5% and increased 5-15% when combined with insulin therapy. Telmisartan, an angiotensin receptor blocker, has anti-hypertensive effects and improve insulin resistance. Telmisartan effect on peroxisome proliferator activated receptor γ agonist and has the same structure of the group thiazolidindion, pioglitazone. The research objective was to determine the effects of telmisartan and metformin on insulin resistance in metabolic syndrome patients with insulin therapy. Methods: using a before-after design. The study was conducted in the internal medicine clinic of the department of endocrinology Dr. Sardjito Hospital Yogyakarta. Subjects were patients who met the diagnosis of metabolic syndrome based on the IDF 2005, hypertension and received insulin therapy. Subjects given metformin and telmisartan therapy for 12 weeks. Subjects examined HOMA IR before and after treatment. The average decrease in HOMA IR was tested by paired t-test or Wilcoxon tests. P value < 0.05 was considered significant. Result: total sample were 27 subjects. Data analysis was performed on 11 subjects. Fasting blood glucose before and after treatment was significantly decreased (p<0,001) whereas the fasting insulin levels increased. HOMA IR was significantly decreased after treatment {p = 0,004 (5,79 � 20,26), CI 95%}. Conclusion: this study found decreased insulin resistance significantly in patients with the metabolic syndrome of insulin therapy who received metformin and telmisartan.
first_indexed 2024-03-13T23:03:03Z
format Thesis
id oai:generic.eprints.org:123345
institution Universiti Gadjah Mada
last_indexed 2024-03-13T23:03:03Z
publishDate 2013
publisher [Yogyakarta] : Universitas Gadjah Mada
record_format dspace
spelling oai:generic.eprints.org:1233452016-03-04T08:43:35Z https://repository.ugm.ac.id/123345/ EFEK PEMBERIAN METFORMIN DAN TELMISARTAN TERHADAP RESISTENSI INSULIN PADA PASIEN SINDROM METABOLIK DENGAN TERAPI INSULIN , Siswi Oktariani , Dr. R. Bowo Pramono, SpPD-KEMD ETD Background: Recommendations for therapy of insulin resistance are metformin and thiazolidindion. Side effects of thiazolidindion due to peripheral edema occurs to 2- 5% and increased 5-15% when combined with insulin therapy. Telmisartan, an angiotensin receptor blocker, has anti-hypertensive effects and improve insulin resistance. Telmisartan effect on peroxisome proliferator activated receptor γ agonist and has the same structure of the group thiazolidindion, pioglitazone. The research objective was to determine the effects of telmisartan and metformin on insulin resistance in metabolic syndrome patients with insulin therapy. Methods: using a before-after design. The study was conducted in the internal medicine clinic of the department of endocrinology Dr. Sardjito Hospital Yogyakarta. Subjects were patients who met the diagnosis of metabolic syndrome based on the IDF 2005, hypertension and received insulin therapy. Subjects given metformin and telmisartan therapy for 12 weeks. Subjects examined HOMA IR before and after treatment. The average decrease in HOMA IR was tested by paired t-test or Wilcoxon tests. P value < 0.05 was considered significant. Result: total sample were 27 subjects. Data analysis was performed on 11 subjects. Fasting blood glucose before and after treatment was significantly decreased (p<0,001) whereas the fasting insulin levels increased. HOMA IR was significantly decreased after treatment {p = 0,004 (5,79 � 20,26), CI 95%}. Conclusion: this study found decreased insulin resistance significantly in patients with the metabolic syndrome of insulin therapy who received metformin and telmisartan. [Yogyakarta] : Universitas Gadjah Mada 2013 Thesis NonPeerReviewed , Siswi Oktariani and , Dr. R. Bowo Pramono, SpPD-KEMD (2013) EFEK PEMBERIAN METFORMIN DAN TELMISARTAN TERHADAP RESISTENSI INSULIN PADA PASIEN SINDROM METABOLIK DENGAN TERAPI INSULIN. UNSPECIFIED thesis, UNSPECIFIED. http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=63456
spellingShingle ETD
, Siswi Oktariani
, Dr. R. Bowo Pramono, SpPD-KEMD
EFEK PEMBERIAN METFORMIN DAN TELMISARTAN TERHADAP RESISTENSI INSULIN PADA PASIEN SINDROM METABOLIK DENGAN TERAPI INSULIN
title EFEK PEMBERIAN METFORMIN DAN TELMISARTAN TERHADAP RESISTENSI INSULIN PADA PASIEN SINDROM METABOLIK DENGAN TERAPI INSULIN
title_full EFEK PEMBERIAN METFORMIN DAN TELMISARTAN TERHADAP RESISTENSI INSULIN PADA PASIEN SINDROM METABOLIK DENGAN TERAPI INSULIN
title_fullStr EFEK PEMBERIAN METFORMIN DAN TELMISARTAN TERHADAP RESISTENSI INSULIN PADA PASIEN SINDROM METABOLIK DENGAN TERAPI INSULIN
title_full_unstemmed EFEK PEMBERIAN METFORMIN DAN TELMISARTAN TERHADAP RESISTENSI INSULIN PADA PASIEN SINDROM METABOLIK DENGAN TERAPI INSULIN
title_short EFEK PEMBERIAN METFORMIN DAN TELMISARTAN TERHADAP RESISTENSI INSULIN PADA PASIEN SINDROM METABOLIK DENGAN TERAPI INSULIN
title_sort efek pemberian metformin dan telmisartan terhadap resistensi insulin pada pasien sindrom metabolik dengan terapi insulin
topic ETD
work_keys_str_mv AT siswioktariani efekpemberianmetformindantelmisartanterhadapresistensiinsulinpadapasiensindrommetabolikdenganterapiinsulin
AT drrbowopramonosppdkemd efekpemberianmetformindantelmisartanterhadapresistensiinsulinpadapasiensindrommetabolikdenganterapiinsulin